REGULATORY

Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis

March 25, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

While the first “off-year” drug price revision looms in April next year, many in the pharmaceutical industry and healthcare community now see it difficult to implement the plan as scheduled as the government scrambles to rein in the spread of…

To read the full story

Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020

REGULATORY

LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…